



Updated Guidance: Respiratory Isolation and Restrictions in Home and Community Settings





Objectives

- Participant will be able to describe the rationale for changes to existing recommendations
- Participate will be able to summarize key findings from the evidence-based literature
- Participate will be able to list at least three ways changes to these recommendations may impact their TB patients and programs





National Background

Updated guidance published in April of 2024 by the National TB Coalition of

America

Clinical Infectious Diseases









National Tuberculosis Coalition of America (NTCA) Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in Community Settings

Maunank Shah,^{1,6} Zoe Dansky,¹ Ruvandhi Nathavitharana,² Heidi Behm,³ Shaka Brown,⁴ Lana Dov,⁵ Diana Fortune,⁶ Nicole Linda Gadon,⁴ Katelynne Gardner Toren,⁷ Susannah Graves,⁸ Connie A. Haley,⁹ Olivia Kates,^{1,10} Nadya Sabuwala,¹¹ Donna Wegener,¹² Kathryn Yoo,¹³ and Joseph Burzynski¹⁴; on Behalf of the National TB Coalition of America

¹Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA; ²Division of Infectious Diseases, Beth Israel Deaconsess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; ³TB Program, Oregon Health Authority, Portland, Oregon, USA; ⁴We Are TB, Stop TB USA, Atlanta, Georgia, USA; ⁵Washington State Department of Health, Shoreline, Washington, USA; ⁶National Tuberculosis Coalition of America, National TB Nurse Coalition, Atlanta, Georgia, USA; ⁷Public Health Seattle and King County Tuberculosis Control Program, Seattle, Washington, USA; ⁸San Francisco Department of Public Health, San Francisco, California, USA; ⁹Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; ¹⁰Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland, USA; ¹¹Minnesota Department of Health, St. Paul, Minnesota, USA; ¹²National TB Coalition of America, Atlanta, Georgia, USA; ¹³Texas Department of State Health Services, Tuberculosis and Hansen's Diseases Unit (TXDSHS), Society of Epidemiologists in Tuberculosis Control (SETC), Texas, USA; and ¹⁴New York City Department of Health and Mental Hygiene, New York, USA





National Background

- NTCA created a Guideline Development Group (GDG) with broad representation and TB expertise and experience
- Evidence Synthesis Group evaluated scientific literature to inform the GDG
 - Focused on impact of isolation for persons with TB on:
 - Public health outcomes: TB incidence and mortality
 - Patient outcomes: mental health, stigma, costs
- GDG reviewed ethical principles of public health decision-making
- An additional scoping review focused on:
 - Association of sputum smear microscopy results, cough, cavitary disease (based on chest imaging), and tx initiation with potential infectiousness





National Background

- Community settings = Home/residence, workplace, school, etc.
- Consider the potential benefits and harm for the community and the person with TB
- Final decisions should be individually tailored, considering relevant, patientspecific, setting-specific, and contextual information.

Guidance for isolation duration for other settings is unchanged (i.e., correctional facilities, healthcare facilities)





VDH Background

 In response to these updated guidelines, the Virginia TB Program convened a representative workgroup to develop an updated guidance document for TB isolation for use by Virginia's local health departments.





VDH Workgroup

 Mission: In response to these updated guidelines, the Virginia TB Program convened a representative workgroup to develop an updated guidance document for TB isolation for use by Virginia's local health departments.

Goals:

- Critically review and discuss the updated guidelines considering the implications to local health departments, and
- Develop an updated guidance document for use by local health department staff.





VDH Workgroup

Workgroup Members:

- Central Region: Cindy Debusk, Rosalie Bieda, Abi Nimitz, Dr. Saritha Gomadam
- Eastern Region: Marli Laudun, Robie Aubuchon, Michelle Lathrop, Sena Amegbletor
- Northern Region: Dr. Barbara Andrino, Raheleh Farmand, Evelyn Poppell, Emily Astorga, Nancy Lara, Sergio Suarez-Ruesta
- Northwest Region: Katrin Wince, Bindi Pathak, Dr. Allison Baroco, Lauren Padlo
- O Southwest Region: Steve Bailey, Megan Carter, Autumn Logsdon, Kathy Waller, Odessa Dunaway
- DCLS: Kathleen Milloy, Rana Mehr
- VDH TB Program Staff


Workgroup Stakeholders:

- O Jill Grumbine, Newcomer Health Program Manager, VDH
- Jasie Hearn, Division Director, Division of Clinical Epidemiology, VDH
- o Dr. Maria Almond, Piedmont Health District Director
- Tania Shah, TB Survivor, We Are TB
- o Dr. Eric Houpt, TB Program Clinical Consultant, UVA
- O Dr. Tania Thomas, TB Program Clinical Consultant, UVA
- o Dr. Laurie Forlano, Office Director, Office of Epidemiology, VDH
- VDH Community Health Services Leadership





Background – Guidance Changes







What makes public health guidelines unique?

- Weigh responsibility to the community and the public's health with responsibilities to the patient
- Rights-based limitations to public health power





Main take aways from evidence base

- Sputum examination (smear) does not correlate reliably with infectiousness after treatment initiation
- Appropriate treatment rapidly renders a person non-infectious
- Low certainty that isolation reduces TB incidence and mortality
- Moderate certainty that isolation worsens mental health, stigma, finances

Isolation can be considered balancing community and patient well-being given that most people have a low likelihood of infectiousness after at least five DOT doses of appropriate treatment.





Main take aways from evidence base

- Recent Studies: Infectiousness declines rapidly with effective anti-TB therapy (ATT)
 - Cough aerosol sampling (CASS) studies cough aerosols become non culturable within days of ATT initiation
 - Multidrug ATT to which organism is susceptible reduces infectivity 48-72 hours, irrespective of sputum AFB smear status
 - Effect of ATT on *M. tuberculosis* likely decreases transmissibility earlier than it inhibits mycobacterial growth
 - Available evidence from early bactericidal activity studies, human-to-guinea pig transmission studies, cohort studies, and transcriptomic studies suggests that transmissibility declines rapidly (i.e., within 2–3 days) with effective ATT in the majority of PWTB, including those with high pre-ATT bacterial burden assessed by pre-ATT smear positivity or pulmonary cavities on chest X-ray.





Type of Evidence	Brief Summary	Location and Date
Randomized trial	Persons with TB randomized to sanatorium versus home-based treatment with INH and PAS; no difference in LTBI or TB disease among household contacts over 5 y; "major risk to contacts resulted from exposure to patient before diagnosis"	Madras, India, 1956–1959 [16]
Retrospective cohort	Persons with TB discharged from the hospital on treatment while still TB culture positive (majority also AFB smear positive) compared with persons with TB who were AFB smear and culture negative at discharge from hospital; no difference in TST conversion among household contacts	Arkansas, 1967–1971 [17]
Experiment	Guinea pigs susceptible to TB infection exposed to air vented from a TB ward; treatment of persons with TB with INH, PAS, and SM reduced transmission to guinea pigs by 98% immediately compared with untreated persons with TB	Baltimore VA TB Ward, 1959–1961 [18]
Experiment	Guinea pigs susceptible to TB infection exposed to air vented from MDR TB ward; TST conversions in guinea pigs showed infection of 1 (1%) of guinea pigs after 3 mo of exposure to 27 persons with MDR (most AFB smear positive) on treatment with regimen of levofloxacin, kanamycin, ethionamide, and either ethambutol or prothionamide	South Africa, ~2007–2012 [19]
Transcriptomic analysis	Analysis of TB isolates from respiratory aerosols of 7 persons with drug-susceptible TB on TB treatment with rifampin, INH, PZA, and ethambutol showed immediate downregulation of transcription of genes involved in TB virulence and infectiousness after 1 d of treatment	Mumbai, India, 2018–202 [20]


Abbreviations: AFB, acid-fast bacilli; INH, isoniazid; MDR, multidrug resistant; LTBI, latent tuberculosis infection; PAS, para-aminosalicyclic acid; PZA, pyrazinamide; SM, streptomycin; TB, tuberculosis; TST, tuberculin skin test.





Transmission Risk - Multifactorial

- Infectiousness potential
 - Bacillary burden
 - Clinical picture
 - Radiographic findings
- Environment
 - Ventilation
- Type of contact
 - Duration
 - Proximity
- Susceptibility of contact
 - Immune status







Main NTCA TB Isolation Guidelines Recommendation

To account for individual variability, time to conduct clinical and public health assessment, allow rapid molecular drug-susceptibility testing and monitoring of ATT adherence and tolerability, 5 days of continuous effective ATT is recommended as a pragmatic approach to determination of infectiousness.

Effective therapy is defined as a multi-drug ATT regimen to which the organism is susceptible or anticipated to be susceptible.







Isolation and Respiratory Restrictions for Persons with Infectious Active Tuberculosis in Household and Community Settings: Virginia Department of Health Guidance for Local Health Departments

April 18, 2025

This guidance is intended for local health departments. Care and management of anyone with active tuberculosis (pulmonary or extrapulmonary) should be done in coordination with VDH and local health departments.

Summary/Purpose

In light of <u>updated national guidelines</u>¹ released in 2024, this document is designed to assist Virginia Department of Health (VDH) TB clinical teams when making decisions about the use of respiratory isolation and restrictions (RIR) for a person with potentially infectious active TB.

In this document, the term RIR is used to delineate both physical isolation of a person with TB (PWTB) and restrictions on movement or activities that would place the PWTB in contact with other susceptible individuals. RIR is only necessary for persons with infectious (or potentially infectious) active TB disease, to reduce risk of infection of others, and it is not recommended for persons with noninfectious forms of TB (i.e., localized extrapulmonary TB without pulmonary or laryngeal involvement, as confirmed by sputum bacteriologic studies and/or chest imaging). RIR is not used for persons diagnosed with latent TB infection (LTBI), which is not infectious.

These guidelines reflect changes to recommendations for implementation of RIR in a household or general community setting (e.g., workplace, school). Recommendations for healthcare (e.g., hospitals, nursing homes) and congregate settings (e.g., correctional facilities, homeless shelters, assisted living facilities) are unchanged and not addressed in this document. Resources for these settings are available from the Centers for Disease Control and Prevention (CDC).

Table 1. RIR recommendations based on clinical characteristics and other risk fa

Group	Clinical Charac		ı	Recommende	d RIR	Other cons
1	Extrapulmonary concern for pull laryngeal involve Child under the without adult typ cavitation, posit smears etc. (cor VDH TB) Asymptomatic concerns the control of the contr	apulmonary TB with no empression of the months of the mont		t consistent negative ta smears hours apart	Additional isolation needed for extrapu draining open wour	
2	Suspected or confirmed multi-drug-resistant TB or mono-resistance to rifampin		Extensive restriction until release deemed appropriate by clinical care team		RIR may be extend consequences of the resistant disease, a children <5 years o immunosuppresset a congregate settin home) or work (e.g. Reassess RIR nee health and wellbe	
	Extensive disea	se	clie to a	tensive restricent tolerating an appropriate TE	d adherent treatment	Moderate restriction depending on the F and activities. atory Isolation and
						Restriction
3		Movement Restrictions		General	Strictly lin	nit movement to an aquich as home or other
	Lives or works			Indoor Activities	home/resid healthcare	or activities beyond lence (i.e., may attend visit as determined the with local health depa
	risk community (e.g., househo			Outdoor		e outdoor activities wit

children <5 vea

Minimizing

Additional

Exposure

Visitors

Risk

daycare, group Works in a high

congregate set

nursing home

facility)

None of the ab




Figure 1: Algorithm to Assist VDH TB Clinical Teams in

Decision Making for Respiratory Isolation and Restrictions for Patients with TB Disease in Home and Community Settings

Modified is olation until chest imaging results

Start

home/residence and for any other indoor activities.

Consider PPE for close contacts (e.g., surgical masks).

filtration, negative pressure if visiting healthcare setting).

Make efforts to improve ventilation (open windows during car transportation, HEPA

(as resources permit). Consider providing TB education resources in appropriate languages.

Avoid visitors during the period of restriction/isolation. If visitors are unavoidable, encourage visiting outside or while masked

Any of the following:





Major Shifts



Reduced emphasis on smear status after initiation of appropriate TB treatment



Increased emphasis on effectiveness of appropriate TB treatment



Potential for more clients to be released sooner





	Table 1. RIR recommendations based on clinical characteristics and other risk factors				
Group	Clinical Characteristics and Risk Factors	Recommended RIR	Other considerations		
1	Extrapulmonary TB with no concern for pulmonary or laryngeal involvement Child under the age of 10 without adult type cavitation, positive sputa smears etc. (consult with VDH TB) Asymptomatic clients with a B1 EDN classification	Modified isolation until chest imaging results not consistent with active TB and negative results from 3 sputa smears collected at least 6 hours apart (if applicable) are available	 Additional isolation considerations are needed for extrapulmonary sites with draining open wounds infected with TB. 		
2	Suspected or confirmed multi-drug-resistant TB or mono-resistance to rifampin	Extensive restriction until release deemed appropriate by clinical care team	RIR may be extended due to potential consequences of the spread of drugresistant disease, amticipated exposure to children <5 years of age or to immunosuppressed individuals, return to a congregate setting to live (e.g., group home) or work (e.g., correctional facility). Reassess RIR needs and mental health and wellbeing each week		
3	Extensive disease	Extensive restriction until client tolerating and adherent to appropriate TB treatment for 5-14 DOT doses AND clinical improvement if symptomatic (e.g., reduced cough, fever resolution, etc.) May consider additional days of extensive restrictions depending on extent of illness and clinical care team's assessment	Moderate restriction may be appropriate depending on the PWTB's living situation and activities. RIR may also be extended despite a PWTB's low infectious potential due to community risks including anticipated exposure to children <5 years of age or to immunosuppressed individuals, return to a congregate setting to live (e.g., group home) or work (e.g., correctional facility). Reassess RIR needs and mental health and wellbeing each week		
4	Lives or works in a higher- risk community setting (e.g., household with children <5 years of age, daycare, group home) Works in a high-risk congregate setting (e.g., nursing home, correctional facility)	Moderate restriction until client tolerating and adherent to appropriate TB treatment for 5-14 DOT doses AND clinical improvement if symptomatic (e.g., reduced cough, fever resolution, etc.)	RIR may be extended despite a PWTB's low infectious potential due to community risks including anticipated exposure to children <5 years of age or to immunosuppressed individuals, return to a congregate setting to live (e.g., group home) or work (e.g., correctional facility). Reassess RIR needs and mental health and wellbeing each week		
5	None of the above	Moderate restriction until tolerating and adherent to appropriate TB treatment for at least 5 DOT doses			





Group	Clinical Characteristics and Risk Factors	Recommended RIR	Other considerations	
1	Extrapulmonary TB with no concern for pulmonary or laryngeal involvement Child under the age of 10 without adult type cavitation, positive sputa smears etc. (consult with VDH TB) Asymptomatic clients with a B1 EDN classification	Modified isolation until chest imaging results not consistent with active TB and negative results from 3 sputa smears collected at least 8 hours apart (if applicable) are available	Additional isolation considerations are needed for extrapulmonary sites with draining open wounds infected with TB.	





2	Suspected or confirm multi-drug-resistant T mono-resistance to rifampin		RIR may be extended due to potential consequences of the spread of drugresistant disease, anticipated exposure to children <5 years of age or to immunosuppressed individuals, return to a congregate setting to live (e.g., group home) or work (e.g., correctional facility). Reassess RIR needs and mental health and wellbeing each week
---	--	--	--





Extensive disease Extensive restriction until client tolerating and adherent to appropriate TB treatment for 5-14 DOT doses AND clinical improvement if symptomatic (e.g., reduced cough, fever resolution, etc.) May consider additional days of extensive restrictions depending on extent of illness and clinical care team's assessment	 Moderate restriction may be appropriate depending on the PWTB's living situation and activities. RIR may also be extended despite a PWTB's low infectious potential due to community risks including anticipated exposure to children <5 years of age or to immunosuppressed individuals, return to a congregate setting to live (e.g., group home) or work (e.g., correctional facility). Reassess RIR needs and mental health and wellbeing each week
---	--





Moderate restriction until RIR may be extended despite a PWTB's Lives or works in a higherrisk community setting low infectious potential due to community client tolerating and adherent (e.g., household with to appropriate TB treatment for risks including anticipated exposure to 5-14 DOT doses AND clinical children <5 years of age, children <5 years of age or to daycare, group home) improvement if symptomatic immunosuppressed individuals, return to (e.g., reduced cough, fever Works in a high-risk a congregate setting to live (e.g., group resolution, etc.) home) or work (e.g., correctional facility). congregate setting (e.g., nursing home, correctional Reassess RIR needs and mental health and wellbeing each week facility)





5	None of the above	Moderate restriction until tolerating and adherent to appropriate TB treatment for at	
		least 5 DOT doses	
		icast v DOT doses	1






Table 2: Spectrum of Respiratory Isolation and Restrictions for Persons with Tuberculosis

		Extensive Restriction	Moderate Restriction	Modified Isolation
Movement Restrictions	General	Strictly limit movement to an agreed-upon location, such as home or other residence.	Spend majority of time at agreed-upon location, such as home or other residence.	Spend majority of time at agreed- upon location, such as home or other residence.
	Indoor Activities	Limit indoor activities beyond home/residence (i.e., may attend essential healthcare visit as determined through discussion with local health department).	Allow some indoor activities beyond home/residence (e.g., time-sensitive healthcare visit) as determined through discussion with local health department.	Allow indoor activities including time- sensitive healthcare visits.
	Outdoor activities	Allow some outdoor activities without interacting closely with others (e.g., going for a walk).	Allow most outdoor activities as determined through discussion with local health department.	Allow outdoor activities
Minimizing Additional Exposure Risk		Avoid close or prolonged (e.g., multiple hours) contact with those in the home/residence who are vulnerable to TB infection/progression (e.g., children, immunosuppressed individuals). Wear a surgical mask (as resources permit) around vulnerable people in the home/residence and for any other indoor activities. Consider PPE for close contacts (e.g., surgical masks). Make efforts to improve ventilation (open windows during car transportation, HEPA filtration, negative pressure if visiting healthcare setting).		Wear a surgical mask for indoor activities beyond the home/residence.
Visitors		Avoid visitors during the period of restriction/isolation. If visitors are unavoidable, encourage visiting outside or while masked (as resources permit). Consider providing TB education resources in appropriate languages.		











Glossary:

All - Airborne infection isolation

Clinical improvement – Examples of clinical improvement include reduced cough, increased weight, improved appetite, decreased fatigue, decreased night sweats, resolution of fever, resolution of hemoptysis.

Extensive disease – Disease with more extensive damage to the lungs, often identified by the presence of cavitation on chest imaging and sputum smear and nucleic acid amplification test positivity prior to anti-tuberculosis treatment initiation. Seek clinical consultation to determine if the patient has extensive disease.

Extensive restriction - See Table 2

Higher-risk community setting – These are community settings that are not considered "congregate" settings, but where there may be increased risk for transmission of TB. Examples include schools, factories, group homes, etc. Poor ventilation can increase the risk of certain community settings.

High-risk congregate setting – These are congregate settings where there is increased risk for transmission of TB. Examples include correctional facilities, nursing homes, detention facilities, homeless shelters, etc.

Moderate restriction - See Table 2

Modified isolation - See Table 2

PWTB – Person with tuberculosis, in this document this refers to individuals with infectious TB disease

RIR - Respiratory isolation and restrictions





Scenarios



Scenario 1

- 29-year-old male
- Born in Honduras
- Productive cough x3 weeks, 15 lb weight loss
- IGRA positive, x-ray shows cavity
- Initial sputa 3+, PCR positive for TB, no rpoB detected
- No history of prior TB/LTBI treatment
- Works alone outside
- Lives with one roommate
- Has received 7 DOT doses of RIPE and reports decreased cough





Scenario 1 - Decision

- Consider severity of disease
 - Extensive disease (smear+, cough, cavity)
- Consider other risk
 - Works outside, alone
 - Lives with one roommate
 - Lower risk





Scenario 1 - Decision

- Determine duration and level of isolation and restriction
 - Has completed 7 DOT doses of RIPE
 - Decreased cough

Extensive disease Extensive restriction until Moderate restriction may be appropriate client tolerating and adherent depending on the PWTB's living situation to appropriate TB treatment and activities. for 5-14 DOT doses AND RIR may also be extended despite a clinical improvement if PWTB's low infectious potential due to symptomatic (e.g., reduced community risks including anticipated cough, fever resolution, etc.) exposure to children <5 years of age or May consider additional days to immunosuppressed individuals, return of extensive restrictions to a congregate setting to live (e.g., depending on extent of illness group home) or work (e.g., correctional and clinical care team's facility). Reassess RIR needs and mental assessment health and wellbeing each week





Scenario 1 - Decision

Release from isolation

- 7 DOT doses completed (meets 5-14 day threshold)
- Clinical improvement
- No new exposures at home (1 roommate)
- Low risk work environment (works alone, outside)



Scenario 2

- 80-year-old male from Vietnam
- IGRA positive
- 3-month history of cough, fevers, weight loss
- Abnormal x-ray, no cavities
- Does not work
- Diabetic
- Lives alone
- Initial smears negative, PCR negative
- Clinical TB diagnosis
- Starting TB treatment today





Scenario 2 - Decision


- Consider severity of disease
 - Not extensive disease (cough, but smear and PCR -, no cavities)
 - DM; SDLs indicated
- Consider other risk
 - Lives alone
 - Not working
 - Lower risk





Scenario 2 - Decision

Determine duration of isolation and level of restriction







Scenario 2 - Decision

Moderate restriction for 5 days of DOT

Moderate Restriction

Spend **majority of time** at agreed-upon location, such as home or other residence.

Allow **some** indoor activities beyond home/residence (e.g., time-sensitive healthcare visit) as determined through discussion with local health department.

Allow **most** outdoor activities as determined through discussion with local health department.



Scenario 3

- 25-year-old woman
- Born in Peru
- Recent weight loss, hemoptysis, night sweats
- Hx of partial treatment for TB disease as a child
- Initial sputa smears 3+, PCR positive, rpoB mutation detected, culture growing
 - MDDR results pending
- Works in a daycare
- Has not started regimen yet





Scenario 3 - Decision

- Consider severity of disease
 - Extensive disease (smear+, cough, rifampin resistance)
- Consider other risk
 - Daycare worker
 - High risk





Scenario 3 - Decision

Determine duration of isolation and level of restriction

Extensive restriction until Suspected or confirmed RIR may be extended due to potential multi-drug-resistant TB or release deemed appropriate by consequences of the spread of drugmono-resistance to clinical care team resistant disease, anticipated exposure to children <5 years of age or to rifampin immunosuppressed individuals, return to 2 a congregate setting to live (e.g., group home) or work (e.g., correctional facility). Reassess RIR needs and mental health and wellbeing each week





Scenario 3 - Decision

Extensive restriction until release deemed appropriate by clinical care team

	Extensive Restriction
General	Strictly limit movement to an agreed-upon location, such as home or other residence.
Indoor Activities	Limit indoor activities beyond home/residence (i.e., may attend essential healthcare visit as determined through discussion with local health department).
Outdoor activities	Allow some outdoor activities without interacting closely with others (e.g., going for a walk).





TABLE 4.

Criteria for Release from Isolation to High and Lower Risk Settings*

Patient Category	Setting	Criteria
TB case (or suspect on treatment for TB) at increased risk for MDR-TB	High or Lower risk	Obtain direct NAAT, if available, for RIF and/or INH resistance. If direct NAAT not available, while phenotypic DST for RIF is pending, at the discretion of the local TB controller, either criteria for patients with known MDR-TB or criteria for patients not at increased risk of MDR-TB may be applied.
Known MDR-TB case	High risk	Three consecutive respiratory specimens collected on separate days, including at least one early AM or induced sputum, or BAL, are AFB smear negative, and no subsequent sputum specimen is AFB smear positive; At least 14 daily doses of treatment for MDR-TB taken and tolerated by DOT; Clinical improvement; and At least 2 consecutive negative sputum cultures without a subsequent positive culture.
	Lower risk**	Three consecutive sputum specimens collected on separate days are AFB smear negative; At least 14 daily doses of treatment for MDR-TB taken and tolerated by DOT; and Clinical improvement.

Definitions:

High Risk Setting

- A housing or work setting in which others will share air with the TB patient and which is characterized by 1 or more of the following factors:
 - A large number or high density of persons.
 - The presence of persons at high risk of progression to active TB disease (e.g., children < 5, persons with HIV infection)
 - The presence of persons who have not been previously exposed to the TB patient.

Lower Risk Setting

- · A residential setting not characterized as high risk, and:
 - No other persons will share the air with the TB patient; OR
 - Other persons who will share the air with the TB patient are not at increased risk for progression to TB disease if infected; OR
 - All persons at increased risk of progression to TB disease if infected, including all children under the age of 5 years, who will share the air with the TB patient, have been previously exposed to the TB patient, have had a complete medical evaluation and have been started on therapy, including window period treatment for presumed LTBI (TB1),as appropriate.
- A work setting not characterized as high risk, and in which no contacts are known or reasonably expected to be at increased risk of progression to TB disease if infected



Scenario 4

- 44 y/o immigrated from Philippines many years ago
- Seen at local hospital in March
 - Smear positive, no NAA
 - Culture positive three weeks later
 - Asymptomatic, no cavities
- New sputum testing smear and NAA negative, culture pending
- Started on RIPE
- Works as special needs teacher with pre-K 5th grade at local elementary school
 - Significant contact with 50-60 kids (10 under age 5)
 - Broader school population ~300 kids
- Patient: concerned about stigma/work backlash





Scenario 4 - Decision

- Classify severity of disease
 - Not extensive disease
- Consider other risk
 - Higher risk work setting





Scenario 4 - Decision

Determine duration of isolation and level of restriction

4

- Lives or works in a higherrisk community setting (e.g., household with children <5 years of age, daycare, group home)
- Works in a high-risk congregate setting (e.g., nursing home, correctional facility)
- Moderate restriction until client tolerating and adherent to appropriate TB treatment for 5-14 DOT doses AND clinical improvement if symptomatic (e.g., reduced cough, fever resolution, etc.)
- RIR may be extended despite a PWTB's low infectious potential due to community risks including anticipated exposure to children <5 years of age or to immunosuppressed individuals, return to a congregate setting to live (e.g., group home) or work (e.g., correctional facility).
- Reassess RIR needs and mental health and wellbeing each week





Scenario 4 - Decision

Moderate restriction for 5-14 day of DOT

 Given vulnerability of school setting, likely more days out of work (e.g., after 14 DOT doses), but perhaps allowing non-work activities sooner (e.g., after 5 DOT doses)



Scenario 5

- B1 from Afghanistan
- Abnormal x-ray abroad, no cavity, no symptoms
- IGRA positive
- No hx of treatment
- Lives with partner and school-aged children
- Works in office setting





Scenario 5 - Decision

- Classify severity of disease
 - Not extensive/possibly no disease
- Consider other risk
 - Lower risk





Scenario 5 - Decision

Determine duration of isolation and level of restriction

1

- Extrapulmonary TB with no concern for pulmonary or laryngeal involvement
- Child under the age of 10 without adult type cavitation, positive sputa smears etc. (consult with VDH TB)
- Asymptomatic clients with a B1 EDN classification
- Modified isolation until chest imaging results not consistent with active TB and negative results from 3 sputa smears collected at least 8 hours apart (if applicable) are available
- Additional isolation considerations are needed for extrapulmonary sites with draining open wounds infected with TB.





Scenario 5 - Decision

Modified isolation until chest imaging results not consistent with active TB and negative results from 3 sputa smears collected at least 8 hours apart (if applicable) are available

Modified Isolation

Spend **majority of time** at agreedupon location, such as home or other residence.

Allow indoor activities including timesensitive healthcare visits.

Allow outdoor activities

 Wear a surgical mask for indoor activities beyond the home/residence.





Questions and Further Discussion





Where to find documents:

- www.vdh.virginia.gov/tuberculosis/tb-disease/
 - Treatment/Management
 - VDH Guidelines and Recommendations: <u>Isolation and Respiratory Restrictions for Persons with Infectious Active TB in Household and Community Settings: VDH Guidance for Local Health Departments (NEW)</u>
 - National Guidelines and Recommendations: <u>NTCA Guidelines for Respiratory</u> <u>Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in</u> Community Settings (2024)

When TB bacteria become active (multiplying in the body) and the immune system can't stop the bacteria from growing, this is called Tuberculosis (TB) disease. TB disease will make a person sick. People with TB disease may spread the bacteria to people with whom they spend many hours.


It is very important that people who have TB disease are treated, finish the medicine, and take the drugs exactly as prescribed. If they stop taking the drugs too soon, they can become sick agains' if they do not take the drugs correctly, the TB bacteria that are still alive may become resistant to those drugs. TB that is resistant to drugs is gains' if they do not take the drugs correctly, the TB bacteria that are still alive may become resistant to those drugs. TB that is resistant to drugs is gains' if they do not take the drugs correctly, the TB bacteria that are still alive may become resistant to those drugs. TB that is resistant to drugs is gains' if they do not take the drugs correctly, the TB bacteria that are still alive may become resistant to those drugs. TB that is resistant to drugs is gains' if they do not take the drugs correctly, the TB bacteria that are still alive may become resistant to those drugs. TB that are still alive may become resistant to those drugs. TB that are still alive may become resistant to those drugs. TB that are still alive may become resistant to those drugs. TB that are still alive may become resistant to those drugs. TB that are still alive may become resistant to those drugs. TB that are still alive may become resistant to those drugs. TB that are still alive may become resistant to those drugs. TB that are still alive may become resistant to those drugs. TB that are still alive may become resistant to those drugs. TB that are still alive may become resistant to those drugs. TB that are still alive may become resistant to those drugs are still alive may become resistant to those drugs are still alive may become resistant to those drugs are still alive may become resistant to those drugs a


Treatment/Management





Help us collect some data about implementation!









Thank you!

Contact:

laura.r.young@vdh.virginia.gov

General TB email:

tuberculosis@vdh.virginia.gov